 2. The follow-up for patients in the largest trial using standard-dose imatinib the IRIS trial, with 553 patients in treated with imatinib has been limited after the first 12 months. For example, the rate of molecular responses after the first 12 months of therapy was not obtained as samples stopped being collected at that time point. 